Q3 2025 Harmony Biosciences Holdings Inc Earnings Call Transcript

Nov 4, 2025 / 01:30 PM GMT

Release Date Price: $30.72 (+4.74%)

Transcript 10-Q8-K

Key Points

Positve

Harmony Biosciences Holdings Inc (HRMY) reported a strong Q3 2025 with $239.5 million in net revenue, representing a 29% year-over-year growth.
The company raised its full-year revenue guidance to $845 to $865 million, reflecting strong performance and momentum.
Harmony Biosciences Holdings Inc (HRMY) achieved the highest number of quarterly patient additions for Wakix since its launch, with an average of 500 new patients added.
The company has a robust late-stage pipeline with multiple catalysts expected over the next several years, including two phase 3 trials for narcolepsy and idiopathic hypersomnia.
Harmony Biosciences Holdings Inc (HRMY) maintains a strong financial position with $778 million in cash and cash equivalents, enabling strategic investments and potential acquisitions.

Negative

The ZYN002 phase 3 reconnect study in Fragile X syndrome did not meet its primary endpoint due to higher than expected placebo response.
Total operating expenses increased to $114.3 million in Q3 2025 from $81.6 million in the same quarter of 2024, driven by pipeline investments and commercialization efforts.
The company faces potential competition from emerging orexin agonists, which could impact Wakix's market position post-2026.
There is uncertainty regarding the timing and impact of trade inventory fluctuations, which could affect quarterly revenue outcomes.
The ZYN002 program in 22q11.2 deletion syndrome has been paused pending a full review of the reconnect data, indicating potential delays in pipeline advancement.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

HRMY.OQ - Harmony Biosciences Holdings Inc
Q3 2025 Harmony Biosciences Holdings Inc Earnings Call
Nov 04, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning. My name is Madison and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Bioscience's 3rd quarter 2025 Financial results conference call. All participants have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question at that time, please press 1 on your telephone keypad. Please be advised that today's conference may be recorded. Lastly, if you should require operator assistance, please press 0. I will now turn the call over to Matthew Beck. Please go ahead.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.